Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02348294
Other study ID # NL50794.068.14
Secondary ID
Status Not yet recruiting
Phase N/A
First received January 22, 2015
Last updated January 27, 2015
Start date February 2015

Study information

Verified date January 2015
Source Maastricht University Medical Center
Contact Luuk de Wert, MD
Phone +31618074833
Email luuk.wertde@mumc.nl
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

1. The objective of this study is to acquire knowledge about the development of reactive hyperaemia and inflammatory responses of the skin after shear- force and pressure loading. We want to investigate if patients with diabetes type 2 will develop more skin damage, because of a decreased microvascular function.

2. The second objective of this study is: to investigate if the cytokine production of the skin is increased in patients with type 2 diabetes with a history of Charcot osteoarthropathy in comparison with patients with neuropathy without a history of Charcot osteoarthropathy.

The participant is asked to put his left arm on a support cushion. Then we mark an area of 2.5 cm x 3 cm with a permanent marker at the plantar aspect of the left fore-arm and the adhesive side of a Sebutape is placed within this area for collection of IL-1α/ total protein concentrations in a non- loaded situation (event 1) for two minutes. Second, we measure the cutaneous blood cell flux within the borders of the marked area with a Laser doppler. Finally, we measure the erythema index in this area with a colorimeter. Then we place the shear- pad over the marked area we apply 9,8 Newton (N) pressure with 19 N shear- force for half an hour. After this period a new Sebutape is placed for two minutes, followed by cutaneous blood cell flux and the erythema index measurement within the borders of the marked area. We repeat these measures after 15 minutes, 30 minutes, 45 minutes and 60 minutes, At the same time we performed the same experiment at the right arm, but instead of loading this arm with shear- force and pressure, we apply only 9,8 N pressure at this arm. The same measures with the sebutape, laser doppler and colorimeter are done before and after loading of the skin. The measures are repeated at 15 minutes, 30 minutes, 45 minutes and 60 minutes.


Description:

1. Pressure ulcers, also known as bedsores occurs as a result of mechanical loading (combination of pressure and shear- force) of the skin. We proved that IL-1alpha (measurement of skin damage) and reactive hyperaemia (RH) are increased after a combined loading of pressure and shear- force with our own developed shear- force model. This RH is probably a protective mechanism of the loaded skin and is clinically seen as blanchable erythema. Blanchable erythema is seen as an important risk indicator for the development of pressure ulcers. Patients with Diabetes Mellitus type 2, however, will develop less blanchable erythema (RH), because of a decreased micro vascular function. Therefore, they will get less preventive measures against pressure ulcers. We do expect, however, that more skin damage occurs when RH is decreased, so we want to investigate if patients with type 2 diabetes (with or without neuropathy) will develop less RH and more skin damage (IL-1alpha) after shear force application at the skin compared with healthy volunteers.

2. Charcot- neuro- osteoarthropathy is a rare, but serious complication of polyneuropathy. Most of the times it occurs at the feet in patients with diabetes with neuropathy. It is associated with inflammation, hyperaemia, bone deformation and luxation of the joints. The pathogenesis is not well understood: the hyperemic response of the skin to external stimuli is increased, but we do not know if this hyperaemia is a result of primary hypervascularity or a increase in primary cytokines. Our research model gives us the opportunity to investigate if: the local cytokine production is increased in patients with diabetes type with neuropathy and a history of charcot osteoarthropathy after shear- force application at the skin compared with patients with type 2 diabetes with neuropathy.

Study population:

Group A:

- Healthy volunteers

- > 40 years

Group B;

- patients with Diabetes Mellitus type 2 (DM) without neuropathy

- age > 40 years

- Valk score < 4

Group C:

- Patients with DM type 2 with neuropathy

- age > 40 years

- Valk score > 4

Group D

- Patients with (pre)- existing Charcot Osteoarhtropathy

- age > 40 years

- Valk score > 4 Primary study parameters/outcome of the study

1. IL-1 α/ total protein ratio

2. Bloodflow of the skin (in flux )

3. Erythema index of the skin

The participant is asked to put his left arm on a support cushion. Then we mark an area of 2.5 cm x 3 cm with a permanent marker at the plantar aspect of the left fore-arm and the adhesive side of a Sebutape is placed within this area for collection of IL-1α/ total protein concentrations in a non- loaded situation (event 1) for two minutes. Second, we measure the cutaneous blood cell flux within the borders of the marked area with a Laser doppler. Finally, we measure the erythema index in this area with a colorimeter. Then we place the shear- pad over the marked area we apply 9,8 Newton (N) pressure with 19 N shear- force for half an hour. After this period a new Sebutape is placed for two minutes, followed by cutaneous blood cell flux and the erythema index measurement within the borders of the marked area. We repeat these measures after 15 minutes, 30 minutes, 45 minutes and 60 minutes, At the same time we performed the same experiment at the right arm, but instead of loading this arm with shear- force and pressure, we apply only 9,8 N pressure at this arm. The same measures with the sebutape, laser doppler and colorimeter are done before and after loading of the skin. The measures are repeated at 15 minutes, 30 minutes, 45 minutes and 60 minutes.

Outcomes; IL-1alpha/ total protein- ratio Cutaneous blood cell flux Erythema index


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date
Est. primary completion date January 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Group A:

- Healthy volunteers

- > 40 years

Group B;

- patients with Diabetes Mellitus type 2 (DM) without neuropathy

- age > 40 years

- Valk score < 4

Group C:

- Patients with DM type 2 with neuropathy

- age > 40 years

- Valk score > 4

Group D

- Patients with (pre)- existing Charcot Osteoarhtropathy

- age > 40 years

- Valk score > 4

Exclusion Criteria:

- Trauma fore arms

- Skin diseases (psoriasis, eczema)

- NSAID use in last seven days

- Bèta blocker use

- Corticosteroids

- Auto- immune diseases

- Muscular dystrophy

- Malignancy

- Participant is unable to give informed consent

- Peripheral artery disease (doppler eai <0.9)

- Hab1c percentage last 3 months > 11%

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label


Intervention

Other:
Shear- force 19 newton and 3,9 kpa pressure for half an hour


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Increase in IL-1alpha/ total protein ratio 0, 15, 30, 45, 60 minutes after intervention No
Primary Increase in Cutaneous blood cell flux 0, 15, 30, 45, 60 minutes after intervention No
Primary Increase in erythema index 0, 15, 30, 45, 60 minutes after intervention No
See also
  Status Clinical Trial Phase
Completed NCT01267448 - Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Phase 4
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Terminated NCT02373865 - Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Phase 4
Completed NCT01741181 - Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 Phase 4
Completed NCT01305434 - Mulberry Leaf Extract and Blood Glucose Control in Diabetics Phase 1/Phase 2
Completed NCT01330121 - Bridging the Gap by Transitional Care N/A
Recruiting NCT00992797 - Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity Phase 2
Completed NCT01580904 - Impact of Pharmaceutical Care in Diabetics Patients N/A
Active, not recruiting NCT00728403 - Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes Phase 2
Completed NCT00763815 - GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone Phase 3
Active, not recruiting NCT00529815 - Continuous Glucose Monitoring in Patients With Type 2 Diabetes Phase 4
Completed NCT00517465 - A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus. Phase 1
Completed NCT00119041 - Diabetes Telemedicine Consultation: A Systems Improvement Intervention N/A
Withdrawn NCT00417716 - Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema Phase 3
Withdrawn NCT00600236 - HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population Phase 3
Active, not recruiting NCT05887635 - Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus N/A
Completed NCT03903965 - Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.
Completed NCT02666924 - Cooking Classes for Chinese Canadian Patients Living With Diabetes N/A
Recruiting NCT02501850 - The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Phase 4